---
figid: PMC3841209__cbt-14-703-g9
figtitle: Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib
  to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer
organisms:
- Homo sapiens
organisms_ner:
- Homo sapiens
- Danio rerio
pmcid: PMC3841209
filename: cbt-14-703-g9.jpg
figlink: /pmc/articles/PMC3841209/figure/F9/
number: F9
caption: Figure 9. EGFR and BRAF/ERK signaling pathway.
papertitle: Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib
  to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.
reftext: Mhd Yaser Al-Marrawi, et al. Cancer Biol Ther. 2013 Aug 1;14(8):703-710.
year: '2013'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9274458
figid_alias: PMC3841209__F9
figtype: Figure
redirect_from: /figures/PMC3841209__F9
ndex: bf44b765-df0a-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3841209__cbt-14-703-g9.html
  '@type': Dataset
  description: Figure 9. EGFR and BRAF/ERK signaling pathway.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGFR
  - KRAS
  - NRAS
  - RAF1
  - ARAF
  - BRAF
  - ZHX2
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - ATP7A
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - EPHB2
  - MAPK1
  - MAPK3
  - RPS6KA1
  - RPS6KA2
  - RPS6KA3
  - RPS6KA4
  - RPS6KA5
  - RPS6KA6
  - RPS6KB1
  - RPS6KB2
  - kita
  - ngfra
  - egfra
  - kras
  - raf1a
  - araf
  - braf
  - si:dkey-222f8.3
  - pak2a
  - itpka
  - map2k1
  - map2k2a
  - mapk3
  - Regorafenib
  - Cancer
  - Cardiomyopathy
---
